State of the Art and New Trends from the 2022 Gism Annual Meeting
Ferrero I., Proto CF., Banche Niclot AGS., Marini E., Pascucci L., Piccinini F.
Laboratory Study, published in Int J Mol Sci (2023) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Int J Mol Sci (2023)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 37240248
- PMCID
- PMC10219299
- DOI
- 10.3390/ijms24108902
Abstract (original English)
The 2022 Italian Mesenchymal Stem Cell Group (Gruppo Italiano Staminali Mesenchimali, GISM) Annual Meeting took place on 20-21 October 2022 in Turin (Italy), with the support of the University of Turin and the City of Health and Science of Turin. The novelty of this year's meeting was its articulation, reflecting the new structure of GISM based on six sections: ( 1 ) Bringing advanced therapies to the clinic: trends and strategies, ( 2 ) GISM Next Generation, ( 3 ) New technologies for 3D culture systems, ( 4 ) Therapeutic applications of MSC-EVs in veterinary and human medicine, ( 5 ) Advancing MSC therapies in veterinary medicine: present challenges and future perspectives, ( 6 ) MSCs: a double-edged sword: friend or foe in oncology. National and international speakers presented their scientific works with the aim of promoting an interactive discussion and training for all attendees. The atmosphere was interactive, where ideas and questions between younger researchers and senior mentors were shared in all moments of the congress.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.